Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells

Cellular Immunology

Volumn 198, Issue 2, 1999, Pages 131-138

  Wan, Yonghong ^a   Emtage, Peter ^a   Zhu, Qing ^a   Foley, Ronan ^a   Pilon, Andrew ^a   Roberts, Bruce ^b   Gauldie, Jack ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GLYCOPROTEIN GP 100;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOLOGY; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0033375998     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1006/cimm.1999.1585     Document Type: Article

References (41)

1. Robbins P. F., Kawakami Y. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:1996;628-636.
2. Rosenberg S. A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today. 18:1997;175-182.
3. Kawakami Y., Robbins P. F., Wang R. F., Parkhurst M., Kang X., Rosenberg S. A. The use of melanosomal proteins in the immunotherapy of melanoma. J. Immunother. 21:1998;237-246.
4. Rosenberg S. A., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Restifo N. P., Dudley M. E., Schwarz S. L., Spiess P. J., Wunderlich J. R., Parkhurst M. R., Kawakami Y., Seipp C. A., Einhorn J. H., White D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:1998;321-327.
5. Nestle F. O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332.
6. Hirschowitz E. A., Leonard S., Song W., Ferris B., Leopold P. L., Lewis J. J., Bowne W. B., Wang S., Houghton A. N., Crystal R. G. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther. 5:1999;975-983.
7. Zhai Y., Yang J. C., Kawakami Y., Spiess P., Wadsworth S. C., Cardoza L. M., Couture L. A., Smith A. E., Rosenberg S. A. Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 156:1996;700-710.
8. Rosenberg S. A., Zhai Y., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Restifo N. P., Seipp C. A., Einhorn J. H., Roberts B., White D. E. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90:1998;1894-1900.
9. Zhai Y., Yang J. C., Spiess P., Nishimura M. I., Overwijk W. W., Roberts B., Restifo N. P., Rosenberg S. A. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J. Immunother. 20:1997;15-25.
10. Wan Y., Bramson J. L., Carter R., Graham F. L., Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther. 8:1997;1355-1363.
11. Brossart P., Goldrath A. W., Butz E. A., Martin S., Bevan M. J. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158:1997;3270-3276.
12. Gong J., Chen L., Chen D., Kashiwaba M., Manome Y., Tanaka T., Kufe D. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther. 4:1997;1023-1028.
13. Song W., Kong H. L., Carpenter H., Torii H., Granstein R., Rafii S., Moore M. A., Crystal R. G. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1997;1247-1256.
14. Ribas A., Butterfield L. H., McBride W. H., Jilani S. M., Bui L. A., Vollmer C. M., Lau R., Dissette V. B., Hu B., Chen A. Y., Glaspy J. A., Economou J. S. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 57:1997;2865-2869.
15. Wan Y., Emtage P., Foley R., Carter R., Gauldie J. Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression. Int. J. Oncol. 14:1999;771-776.
16. Hehir K. M., Armentano D., Cardoza L. M., Choquette T. L., Berthelette P. B., White G. A., Couture L. A., Everton M. B., Keegan J., Martin J. M., Pratt D. A., Smith M. P., Smith A. E., Wadsworth S. C. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J. Virol. 70:1996;8459-8467.
17. Kaplan J. M., Armentano D., Sparer T. E., Wynn S. G., Peterson P. A., Wadsworth S. C., Couture K. K., Pennington S. E., St. George J. A., Gooding L. R., Smith A. E. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8:1997;45-56.
18. Hitt M., Bett A. J., Prevec L., Graham F. L. Construction and propagation of human adenovirus vectors. Cell Biology: A Laboratory Handbook. 1998;Academic Press, San Diego. p. 500-512.
19. Juillard V., Villefroy P., Godfrin D., Pavirani A., Venet A., Guillet J. G. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. J. Immunol. 25:1995;3467-3473.
20. Xiang Z. Q., Yang Y., Wilson J. M., Ertl H. C. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology. 219:1996;220-227.
21. Chen P. W., Wang M., Bronte V., Zhai Y., Rosenberg S. A., Restifo N. P. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156:1996;224-231.
22. Houghton A. N. Cancer antigens: Immune recognition of self and altered self. J. Exp. Med. 180:1994;1-4.
23. Bakker A. B., Schreurs M. W., de Boer A. J., Kawakami Y., Rosenberg S. A., Adema G. J., Figdor C. G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1994;1005-1009.
24. Kawakami Y., Rosenberg S. A. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev. Immunol. 14:1997;173-192.
25. Overwijk W. W., Tsung A., Irvine K. R., Parkhurst M. R., Goletz T. J., Tsung K., Carroll M. W., Liu C., Moss B., Rosenberg S. A., Restifo N. P. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:1998;277-286.
26. Schreurs M. W., de Boer A. J., Figdor C. G., Adema G. J. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res. 58:1998;2509-2514.
27. Zitvogel L., Mayordomo J. I., Tjandrawan T., DeLeo A. B., Clarke M. R., Lotze M. T., Storkus W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:1996;87-97.
28. Celluzzi C. M., Mayordomo J. I., Storkus W. J., Lotze M. T., Falo L. D. Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:1996;283-287.
29. Porgador A., Snyder D., Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:1996;2918-2926.
30. + T cells. J. Immunol. 153:1994;2878-2889.
31. Stingl G., Bergstresser P. R. Dendritic cells: A major story unfolds. Immunol. Today. 16:1995;330-333.
32. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:1998;588-594.
33. Toes R. E., Ossendorp F., Offringa R., Melief C. J. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189:1999;753-756.
34. + T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res. 58:1998;296-301.
35. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189:1999;871-876.
36. + T lymphocytes. J. Exp. Med. 189:1999;767-778.
37. + T cells. J. Exp. Med. 189:1999;757-766.
38. Tefany F. J., Barnetson R. S., Halliday G. M., McCarthy S. W., McCarthy W. H. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J. Invest. Dermatol. 97:1991;197-202.
39. + T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J. Immunol. 154:1995;772-779.
40. + CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J. Immunol. 161:1998;1220-1230.
41. Thomas W. D., Hersey P. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95). Int. J. Cancer. 75:1998;384-390.